These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33988738)

  • 1. Optimizing conditioning regimen with low-dose irradiation or busulfan enables the outcome of transplantation from a 6-7/8 HLA-matched donor comparable to that from an 8/8 HLA-matched unrelated donor in severe aplastic anemia patients under 40 years.
    Qin X; Zhu YP; Luo CJ; Zhou M; Huang K; Chen C; Zhang WP; Sun Y; Luo RM; Tang XF; Yang T; Song XM; Hu SY; Sun ZM; Hu J; Wang SQ; Chen J
    Ann Hematol; 2021 Sep; 100(9):2363-2373. PubMed ID: 33988738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Achieved Outcomes Comparable With Matched Unrelated Donor Transplantation in Young Acquired Severe Aplastic Anemia.
    Lu Y; Sun RJ; Zhao YL; Xiong M; Cao XY; Zhang JP; Wei ZJ; Zhou JR; Liu DY; Lu DP
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1881-1887. PubMed ID: 29772350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matched sibling versus matched unrelated allogeneic hematopoietic stem cell transplantation in children with severe acquired aplastic anemia: experience of the polish pediatric group for hematopoietic stem cell transplantation.
    Szpecht D; Gorczyńska E; Kałwak K; Owoc-Lempach J; Choma M; Styczyński J; Goździk J; Dłużniewska A; Wysocki M; Kowalczyk JR; Chybicka A; Pieczonka A; Wachowiak J
    Arch Immunol Ther Exp (Warsz); 2012 Jun; 60(3):225-33. PubMed ID: 22527354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Case for Upfront HLA-Matched Unrelated Donor Hematopoietic Stem Cell Transplantation as a Curative Option for Adult Acquired Severe Aplastic Anemia.
    Marsh JCW; Risitano AM; Mufti GJ
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):e277-e284. PubMed ID: 31129354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-Transplantation Cyclophosphamide-Based Haploidentical versus Matched Unrelated Donor Peripheral Blood Hematopoietic Stem Cell Transplantation Using Myeloablative Targeted Busulfan-Based Conditioning for Pediatric Acute Leukemia.
    Hong KT; Park HJ; Kim BK; An HY; Choi JY; Kang HJ
    Transplant Cell Ther; 2022 Apr; 28(4):195.e1-195.e7. PubMed ID: 35021131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient.
    Maury S; Balère-Appert ML; Chir Z; Boiron JM; Galambrun C; Yakouben K; Bordigoni P; Marie-Cardine A; Milpied N; Kanold J; Maillard N; Socié G;
    Haematologica; 2007 May; 92(5):589-96. PubMed ID: 17488681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
    Güngör T; Teira P; Slatter M; Stussi G; Stepensky P; Moshous D; Vermont C; Ahmad I; Shaw PJ; Telles da Cunha JM; Schlegel PG; Hough R; Fasth A; Kentouche K; Gruhn B; Fernandes JF; Lachance S; Bredius R; Resnick IB; Belohradsky BH; Gennery A; Fischer A; Gaspar HB; Schanz U; Seger R; Rentsch K; Veys P; Haddad E; Albert MH; Hassan M;
    Lancet; 2014 Feb; 383(9915):436-48. PubMed ID: 24161820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
    Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of upfront haploidentical hematopoietic stem cell transplantation and salvage haploidentical hematopoietic stem cell transplantation after immunosuppressive therapy in children with acquired severe aplastic anemia - a multicenter study.
    Luo D; Qu Y; Wang D; Zhang B; Sun M; Xiong H; Lu J; Yang R; Zhao M; Liu H; Jiang H
    Front Immunol; 2024; 15():1384640. PubMed ID: 38720904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia.
    Yoshimi A; Strahm B; Baumann I; Furlan I; Schwarz S; Teigler-Schlegel A; Walther JU; Schlegelberger B; Göhring G; Nöllke P; Führer M; Niemeyer CM
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):425-9. PubMed ID: 24316460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor.
    Devillier R; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Harbi S; Granata A; D'Incan E; Coso D; Chabannon C; Picard C; Etienne A; Calmels B; Schiano JM; Lemarie C; Stoppa AM; Bouabdallah R; Vey N; Blaise D
    Am J Hematol; 2014 Jan; 89(1):83-7. PubMed ID: 24108528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot trial of risk-adapted cyclophosphamide intensity based conditioning and HLA matched sibling and unrelated cord blood stem cell transplantation in newly diagnosed pediatric and adolescent recipients with acquired severe aplastic anemia.
    McGuinn C; Geyer MB; Jin Z; Garvin JH; Satwani P; Bradley MB; Bhatia M; George D; Duffy D; Morris E; van de Ven C; Schwartz J; Baxter-Lowe LA; Cairo MS
    Pediatr Blood Cancer; 2014 Jul; 61(7):1289-94. PubMed ID: 24623601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
    Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopoietic stem cell transplantation without in vivo T-cell depletion for pediatric aplastic anemia: A single-center experience.
    Li S; Wang B; Fu L; Pang Y; Zhu G; Zhou X; Ma J; Su Y; Qin M; Wu R
    Pediatr Transplant; 2018 Aug; 22(5):e13204. PubMed ID: 29744996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A comparative study of unrelated donor and matched-sibling donor allogeneic hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia].
    Zhou J; Fu YW; Liang LJ; Wang Q; Han LJ; Zu YL; Zhang Y; Zhu XH; Yu FK; Fang BJ; Wei XD; Song YP
    Zhonghua Nei Ke Za Zhi; 2016 Dec; 55(12):927-931. PubMed ID: 27916046
    [No Abstract]   [Full Text] [Related]  

  • 19. Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies.
    Kanda J; Long GD; Gasparetto C; Horwitz ME; Sullivan KM; Chute JP; Morris A; Shafique M; Li Z; Chao NJ; Rizzieri DA
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):257-63. PubMed ID: 24269380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favorable preliminary results using TLI/ATG-based immunomodulatory conditioning for matched unrelated donor allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia.
    Pillai A; Hartford C; Wang C; Pei D; Yang J; Srinivasan A; Triplett B; Dallas M; Leung W
    Pediatr Transplant; 2011 Sep; 15(6):628-34. PubMed ID: 21762328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.